Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.

Zhou Y, Zhu J, Wu H, Deng Y, Ji Q

Diabetes therapy : research, treatment and education of diabetes and related disorders28 Aug 2021Cited by 2 (Europe PMC)

PMID34453682PMCIDPMC8479006DOI10.1007/s13300-021-01139-2PepBankPUB-34453682

Read at source PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialSafety outcome
In Chinese patients with type 2 diabetes receiving dulaglutide 1.5 mg, pancreatic enzyme levels (pancreatic amylase, total amylase and lipase) increased from baseline to Week 26 within the normal range.
In plain wordsIn Chinese patients with diabetes receiving dulaglutide, pancreatic enzyme levels rose from baseline but stayed within the normal range.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePancreatic enzyme change from baseline (pancreatic amylase, total amylase, lipase)
Study
n = 203
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Pancreatic enzyme levels increased within the normal range from baseline to Week 26, and no pancreatitis events were confirmed by independent adjudication.
3 context sentences(design, population, supporting numbers)
Summary · context
Changes in pancreatic enzyme (pancreatic amylase, total amylase, and lipase) levels over 26 weeks
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
Report a problemFND-3445368201
02HumanRandomized controlled trialSafety outcome
In Chinese patients with type 2 diabetes receiving dulaglutide, no pancreatitis events were confirmed by independent adjudication.
In plain wordsIn Chinese patients with diabetes receiving dulaglutide, independent reviewers confirmed no pancreatitis events.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAdjudicated pancreatitis
Study
n = 203
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Pancreatic enzyme levels increased within the normal range from baseline to Week 26, and no pancreatitis events were confirmed by independent adjudication.
2 context sentences(design, population, supporting numbers)
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
Report a problemFND-3445368204

Studies that did not test the peptide alone10

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, pancreatic amylase increases were comparable between age subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, pancreatic amylase increases were similar between age subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic amylase change by age
Study
n = 203
Comparator
Age subgroups
Outcome group
Adverse events · Gastrointestinal
Measurements
Pancreatic amylase increase
5.34 U/L
age <60 years
Pancreatic amylase increase
6.71 U/L
age ≥60 years
Source sentences
Summary
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences for age (< 60 years: 5.34; ≥ 60 years: 6.71)
2 context sentences(design, population, supporting numbers)
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368205
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, pancreatic amylase increases were comparable between sex subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, pancreatic amylase increases were similar between sex subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic amylase change by sex
Study
n = 203
Comparator
Sex subgroups
Outcome group
Adverse events · Gastrointestinal
Measurements
Pancreatic amylase increase
5.85 U/L
female
Pancreatic amylase increase
5.66 U/L
male
Source sentences
Summary
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences for
Summary
sex (female: 5.85; male: 5.66)
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368206
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, pancreatic amylase increases were comparable between diabetes duration subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, pancreatic amylase increases were similar between diabetes duration subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic amylase change by diabetes duration
Study
n = 203
Comparator
Diabetes duration subgroups
Outcome group
Adverse events · Gastrointestinal
Measurements
Pancreatic amylase increase
6.15 U/L
diabetes <10 years
Pancreatic amylase increase
4.85 U/L
diabetes ≥10 years
Source sentences
Summary
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences for
Summary
duration of diabetes (< 10 years: 6.15; ≥ 10 years: 4.85)
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368207
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, pancreatic amylase increases were comparable between weight subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, pancreatic amylase increases were similar between weight subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic amylase change by weight
Study
n = 203
Comparator
Weight subgroups
Outcome group
Adverse events · Gastrointestinal
Measurements
Pancreatic amylase increase
6.19 U/L
weight <70 kg
Pancreatic amylase increase
5.39 U/L
weight ≥70 kg
Source sentences
Summary
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences for
Summary
weight (< 70 kg: 6.19; ≥ 70 kg: 5.39)
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368208
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, pancreatic amylase increases were comparable between BMI subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, pancreatic amylase increases were similar between BMI subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic amylase change by BMI
Study
n = 203
Comparator
BMI subgroups
Outcome group
Adverse events · Gastrointestinal
Measurements
Pancreatic amylase increase
5.92 U/L
BMI <25 kg/m2
Pancreatic amylase increase
5.61 U/L
BMI ≥25 kg/m2
Source sentences
Summary
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences for
Summary
BMI (2: 5.92; ≥ 25 kg/m²: 5.61)
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368209
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, pancreatic amylase increases were comparable between baseline HbA1c subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, pancreatic amylase increases were similar between starting HbA1c subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic amylase change by baseline HbA1c
Study
n = 203
Comparator
HbA1c subgroups
Outcome group
Adverse events · Gastrointestinal
Measurements
Pancreatic amylase increase
6.82 U/L
HbA1c <8.5%
Pancreatic amylase increase
4.08 U/L
HbA1c ≥8.5%
Source sentences
Summary
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences for
Summary
HbA1c (< 8.5%: 6.82; ≥ 8.5%: 4.08)
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368210
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, pancreatic amylase increases were comparable between baseline triglyceride subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, pancreatic amylase increases were similar between starting triglyceride subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic amylase change by triglycerides
Study
n = 203
Comparator
Triglyceride subgroups
Outcome group
Adverse events · Gastrointestinal
Measurements
Pancreatic amylase increase
4.94 U/L
triglycerides <2.3 mmol/L
Pancreatic amylase increase
8.04 U/L
triglycerides ≥2.3 mmol/L
Source sentences
Summary
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences for
Summary
triglycerides (< 2.3 mmol/L: 4.94; ≥ 2.3 mmol/L: 8.04)
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368211
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, pancreatic amylase increases were comparable between concomitant oral medication subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, pancreatic amylase increases were similar between oral medication subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic amylase change by concomitant medication
Study
n = 203
Comparator
Concomitant OAM subgroups
Outcome group
Adverse events · Gastrointestinal
Measurements
Pancreatic amylase increase
5.68 U/L
metformin
Pancreatic amylase increase
5.44 U/L
sulfonylurea
Pancreatic amylase increase
5.87 U/L
metformin plus sulfonylurea
Source sentences
Summary
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences for
Summary
and concomitant OAMs (metformin: 5.68; sulfonylurea: 5.44; metformin plus sulfonylurea: 5.87).
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368212
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients receiving dulaglutide, total amylase and lipase increases were similarly comparable across the subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, total amylase and lipase changes were similar across the subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTotal amylase and lipase change across baseline subgroups
Study
n = 203
Comparator
Baseline factor and concomitant OAM subgroups
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Similar results were observed for total amylase and lipase.
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368213
12HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Chinese patients with type 2 diabetes receiving dulaglutide 1.5 mg, lipase change over 26 weeks was similar across baseline-factor and concomitant-medication subgroups.
In plain wordsIn Chinese patients receiving dulaglutide, lipase changes over 26 weeks were similar across baseline and oral medication subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeLipase change across baseline subgroups
Study
n = 203
Comparator
Baseline factor and concomitant OAM subgroups
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Similar results were observed for total amylase and lipase.
3 context sentences(design, population, supporting numbers)
Summary · context
Least-squares mean increase in pancreatic amylase (U/L) from baseline to Week 26 was comparable across all subgroups with no statistically (all P-values > 0.05) or clinically significant between-group differences
Summary · context
This post-hoc subgroup analysis of AWARD-CHN2 investigated the pancreatic safety of dulaglutide in Chinese patients with T2DM, stratified by potential influencing factors.
Summary · context
A total of 203 Chinese patients with T2DM were included in this post-hoc analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3445368214

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01648582

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 774Jul 2012 to Dec 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.